Sequent Scientific Limited (SEQUENT.BO)
INR 136.85
(8.18%)
INR 136.85
(8.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.27 Billion INR | 6.09% |
| 2022 | 7.79 Billion INR | 9.72% |
| 2021 | 7.1 Billion INR | 15.35% |
| 2020 | 6.16 Billion INR | -15.68% |
| 2019 | 7.3 Billion INR | 14.02% |
| 2018 | 6.4 Billion INR | -2.62% |
| 2017 | 6.58 Billion INR | -27.72% |
| 2016 | 9.1 Billion INR | 56.96% |
| 2015 | 5.8 Billion INR | -22.9% |
| 2014 | 7.52 Billion INR | 34.03% |
| 2013 | 5.61 Billion INR | 15.36% |
| 2012 | 4.86 Billion INR | 16.06% |
| 2011 | 4.19 Billion INR | 33.18% |
| 2010 | 3.14 Billion INR | 16.54% |
| 2009 | 2.7 Billion INR | 25.68% |
| 2008 | 2.14 Billion INR | 400.41% |
| 2007 | 429.63 Million INR | 188.32% |
| 2006 | 149 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 8.18 Billion INR | 0.0% |
| 2023 Q4 | 8.27 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 8.27 Billion INR | 6.09% |
| 2022 FY | 7.79 Billion INR | 9.72% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 7.11 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 7.79 Billion INR | 0.0% |
| 2021 Q2 | 6.31 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 7.1 Billion INR | 15.35% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 7.1 Billion INR | 0.0% |
| 2020 Q4 | 6.16 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 6.16 Billion INR | -15.68% |
| 2020 Q2 | 8.05 Billion INR | 0.0% |
| 2019 FY | 7.3 Billion INR | 14.02% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 7.3 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 7.02 Billion INR | 0.0% |
| 2018 Q4 | 6.4 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 6.4 Billion INR | -2.62% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 6.95 Billion INR | 0.0% |
| 2017 Q2 | 7.77 Billion INR | 0.0% |
| 2017 FY | 6.58 Billion INR | -27.72% |
| 2017 Q4 | 6.58 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 9.1 Billion INR | 56.96% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 8.4 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 9.1 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 5.8 Billion INR | 0.0% |
| 2015 Q2 | 4.34 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 5.8 Billion INR | -22.9% |
| 2014 FY | 7.52 Billion INR | 34.03% |
| 2014 Q2 | 5.17 Billion INR | 0.0% |
| 2014 Q4 | 7.52 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 FY | 5.61 Billion INR | 15.36% |
| 2013 Q4 | 5.61 Billion INR | 0.0% |
| 2012 Q2 | 7.3 Billion INR | 0.0% |
| 2012 Q4 | 4.86 Billion INR | 0.0% |
| 2012 FY | 4.86 Billion INR | 16.06% |
| 2011 FY | 4.19 Billion INR | 33.18% |
| 2010 FY | 3.14 Billion INR | 16.54% |
| 2009 FY | 2.7 Billion INR | 25.68% |
| 2008 FY | 2.14 Billion INR | 400.41% |
| 2007 FY | 429.63 Million INR | 188.32% |
| 2006 FY | 149 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 49.156% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 94.564% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -59.707% |
| Granules India Limited | 22.95 Billion INR | 63.954% |
| Indoco Remedies Limited | 10.34 Billion INR | 19.996% |
| Achyut Healthcare Limited | 2.01 Million INR | -410940.735% |
| Ajanta Pharma Limited | 10.71 Billion INR | 22.745% |
| Alkem Laboratories Limited | 48.6 Billion INR | 82.977% |
| Alpa Laboratories Limited | 307.12 Million INR | -2594.125% |
| Brooks Laboratories Limited | 248.6 Million INR | -3228.325% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -126.004% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -69.984% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -292.358% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 92.265% |
| Eris Lifesciences Limited | 38.26 Billion INR | 78.378% |
| FDC Limited | 3.7 Billion INR | -123.073% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 87.292% |
| Gufic Biosciences Limited | 5.59 Billion INR | -47.759% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -261.406% |
| Ipca Laboratories Limited | 33.74 Billion INR | 75.478% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -2688.196% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -178.228% |
| Lasa Supergenerics Limited | 541.92 Million INR | -1426.826% |
| Laurus Labs Limited | 42.71 Billion INR | 80.629% |
| Lupin Limited | 96.23 Billion INR | 91.402% |
| Mankind Pharma Limited | 23.87 Billion INR | 65.343% |
| Medicamen Biotech Limited | 940.36 Million INR | -779.896% |
| Medico Remedies Limited | 438.24 Million INR | -1788.046% |
| Megasoft Limited | 1.85 Billion INR | -346.498% |
| NATCO Pharma Limited | 10.53 Billion INR | 21.437% |
| Piramal Pharma Limited | 74 Billion INR | 88.819% |
| RPG Life Sciences Limited | 1.38 Billion INR | -499.496% |
| Sigachi Industries Limited | 2.53 Billion INR | -226.882% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 95.493% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -306.751% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -610.107% |
| Unichem Laboratories Limited | 8.06 Billion INR | -2.54% |
| Wanbury Limited | 3.15 Billion INR | -162.215% |
| Windlas Biotech Limited | 1.76 Billion INR | -369.408% |
| ZIM Laboratories Limited | 2.08 Billion INR | -297.655% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 88.475% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -112.547% |
| Divi's Laboratories Limited | 18.99 Billion INR | 56.428% |
| Hester Biosciences Limited | 3.59 Billion INR | -130.178% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -223.061% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -955.626% |
| Bal Pharma Limited | 2.51 Billion INR | -229.484% |
| Strides Pharma Science Limited | 37.68 Billion INR | 78.041% |
| Venus Remedies Limited | 1.39 Billion INR | -494.073% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -0.285% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 26.242% |
| Shilpa Medicare Limited | 12.93 Billion INR | 36.02% |
| Aarti Drugs Limited | 11.5 Billion INR | 28.075% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -30.738% |
| Suven Life Sciences Limited | 148.62 Million INR | -5467.349% |
| Ind-Swift Limited | 13.45 Billion INR | 38.495% |
| Valiant Laboratories Limited | 1.05 Billion INR | -681.874% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 22.728% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 41.499% |
| Themis Medicare Limited | 1.88 Billion INR | -338.368% |
| Hikal Limited | 12.99 Billion INR | 36.327% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 89.916% |
| Novartis India Limited | 1.8 Billion INR | -359.4% |
| Wockhardt Limited | 39.87 Billion INR | 79.247% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 86.496% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -2765.055% |
| Neuland Laboratories Limited | 5.49 Billion INR | -50.48% |
| Morepen Laboratories Limited | 4.45 Billion INR | -85.53% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1185.055% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -318.671% |